Chandan Healthcare Limited (NSE: CHANDAN) is a Lucknow, Uttar Pradesh-based company in the Medical Diagnostic Centres industry. With a market capitalisation of ₹582 Cr, it ranks #1,918 by market cap among the 6,197 Indian listed companies on FinBizNet, and #8 of 18 in Medical Diagnostic Centres. At ₹236.00 (as of 16 Nov 2026), the share price is 0.0% below its 52-week high of ₹236.00 and 2.6% above its 52-week low of ₹230.00.
| Current Price | ₹236.00 |
|---|---|
| Market Cap | ₹582 Cr |
| NSE Symbol | CHANDAN |
| Sector | Health Care > Health Care Equipment and Services > Health Care Providers and Services |
| Sub-Industry | Health Care Services > Medical Diagnostic Centres |
| P/E Ratio | 21.9 |
| Return on Equity | 18.43% |
| Return on Assets | 10.74% |
| 52-Week Range | ₹230.00 – ₹236.00 |
| Beta (1Y) | 0.1 |
| Dividend Yield | 0.00% |
| Headquarters | Lucknow, Uttar Pradesh |
| Website | www.chandandiagnostic.com |
| Revenue | ₹81 Cr |
|---|---|
| Net Profit | ₹8 Cr |
| Net Margin | 9.8% |
| EPS (Basic) | ₹3.07 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Promoters held 48.43% of Chandan Healthcare Limited's shares as of Sept 2026, against 49.47% in Sept 2025 (−1.04 percentage points).
Chandan Healthcare Limited operates laboratories in India. The company offers pathology services, such as biochemistry, hematology, histopathology, microbiology, and immunology tests, as well as radiology services, including x-rays, ultrasonography, computed tomography (CT) scan, and magnetic resonance imaging services. The company also provides healthcare and diagnostic services. The company was incorporated in 2003 and is based in Lucknow, India.
1. Diagnostics Services-This segment operates state-of-the-art laboratories that provides pathological investigations and radiology services. 2. NA-NA 3. NA-NA 4. NA-NA
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Dr. Lal Pathlabs Ltd | ₹33,934 Cr | 66.4 | 21.48% | ₹874 Cr | +28.7% |
| Vijaya Diagnostic Centre Limited | ₹14,665 Cr | 84.3 | 19.70% | ₹255 Cr | +38.5% |
| Metropolis Healthcare Limited | ₹11,952 Cr | 61.5 | 13.37% | ₹497 Cr | +14.9% |
| Throcare Technologies Ltd | ₹7,764 Cr | 47.6 | 28.74% | ₹271 Cr | +7.5% |
| SURAKSHA DIAGNOSTIC LIMITED | ₹1,856 Cr | 55.4 | 13.84% | ₹99 Cr | +6.9% |
| Krsnaa Diagnostics Ltd | ₹1,625 Cr | 16.8 | 10.89% | ₹271 Cr | -27.0% |
| Gaudium IVF and Women Health Limited | ₹803 Cr | 27.4 | 16.08% | ₹37 Cr | — |
| Chandan Healthcare Limited | ₹582 Cr | 21.9 | 18.43% | ₹81 Cr | — |
| Aspira Pathlab & Diagnostics Ltd | ₹127 Cr | 2,360 | — | — | +115.2% |
Listed by market capitalisation. Ratios are shown for context only.
Chandan Healthcare Limited is trading at ₹236.00, with a market capitalisation of ₹582 Cr.
Chandan Healthcare Limited operates in the Health Care > Health Care Equipment and Services > Health Care Providers and Services space (Health Care Services > Medical Diagnostic Centres).
Chandan Healthcare Limited has a P/E of 21.9 and a return on equity of 18.43%.
Chandan Healthcare Limited is listed on the NSE under the symbol CHANDAN.
In Q1 FY27, Chandan Healthcare Limited reported revenue of ₹81 Cr and net profit of ₹8 Cr, with basic EPS of ₹3.07 (consolidated, parsed from the company's exchange filing).
Promoters held 48.43% of Chandan Healthcare Limited's shares as of Sept 2026, against 49.47% in Sept 2025 (−1.04 percentage points).
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.